These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8825167)

  • 1. The significance of elevated early follicular-phase follicle stimulating hormone (FSH) levels: observations in unstimulated in vitro fertilization cycles.
    Lindheim SR; Sauer MV; Francis MM; Macaso TM; Lobo RA; Paulson RJ
    J Assist Reprod Genet; 1996 Jan; 13(1):49-52. PubMed ID: 8825167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles.
    Lindheim SR; Sauer MV; Francis MM; Macaso T; Lobo R; Paulson RJ
    Gynecol Obstet Invest; 1997; 43(2):76-8. PubMed ID: 9067710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ; Sauer MV; Lobo RA
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
    Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
    J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Smoothing Gan Reinforcing Shen Method Adjuvantly Treated Poor Response of Diminished Ovari- an Reserve Patients in in vitro Fertilization and Embryo Transfer: a Clinical Study].
    Zhang Z; Zhang XH; He TY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1170-4. PubMed ID: 26677665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels.
    Martin JS; Nisker JA; Tummon IS; Daniel SA; Auckland JL; Feyles V
    Fertil Steril; 1996 Jun; 65(6):1238-40. PubMed ID: 8641506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of oestradiol values in IVF-ET under a combined GnRH analogue--desensitization and simultaneous gonadotrophin stimulation for the outcome of pregnancies.
    Mettler L; Tavmergen EN
    Hum Reprod; 1989 Nov; 4(8 Suppl):59-64. PubMed ID: 2533218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of pure FSH alone or in combination for ovulation stimulation in in vitro fertilization.
    Acosta AA; Bernardus RE; Jones GE; Garcia J; Rosenwaks Z; Simonetti S; Veeck LL; Jones D
    Acta Eur Fertil; 1985; 16(2):81-99. PubMed ID: 3929523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
    Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
    Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting pregnancy success of human in-vitro fertilization in unstimulated cycles.
    Paulson RJ; Sauer MV; Francis MM; Macaso T; Lobo RA
    Hum Reprod; 1994 Aug; 9(8):1571-5. PubMed ID: 7989524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVF performance of women who have fluctuating early follicular FSH levels.
    Lass A; Gerrard A; Abusheikha N; Akagbosu F; Brinsden P
    J Assist Reprod Genet; 2000 Nov; 17(10):566-73. PubMed ID: 11209537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human chorionic gonadotropin or human recombinant follicle-stimulating hormone (FSH)-induced ovulation and subsequent fertilization and early embryo development in hypophysectomized FSH-primed mice.
    Wang XN; Greenwald GS
    Endocrinology; 1993 May; 132(5):2009-16. PubMed ID: 8477652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super high estradiol response to gonadotropin stimulation in patients undergoing in vitro fertilization.
    Diamond MP; Buchholz T; Boyers SP; Lavy G; Shapiro BS; DeCherney AH
    J In Vitro Fert Embryo Transf; 1989 Apr; 6(2):81-4. PubMed ID: 2498447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous luteinizing hormone (LH) surges are associated with more rapidly increasing estradiol (E2) and follicle stimulating hormone (FSH) in in vitro fertilization and embryo transfer.
    Kreiner D; Droesch K; Itskovitz J; Liu HC; Navot D; Rosenwaks Z
    J In Vitro Fert Embryo Transf; 1988 Oct; 5(5):265-7. PubMed ID: 3148022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.